Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Lipid disorders and atherosclerosis in children" and "Society guideline links: Obesity in adults".)
International
●Endocrine Society (ES): Clinical practice guideline for lipid management in patients with endocrine disorders (2020)
●ES: Clinical practice guideline on primary prevention of ASCVD and T2DM in patients at metabolic risk (2019)
●ES: Clinical practice guideline on evaluation and treatment of hypertriglyceridemia (2012)
Canada
●College of Family Physicians of Canada (CFPC): Clinical practice guidelines – PEER simplified lipid guideline, update (2023)
●Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE): Guideline for the prevention and management of cardiovascular disease in primary care, update (2022)
●Canadian Cardiovascular Society (CCS): Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults (2021)
●CCS: Position statement on familial hypercholesterolemia, update (2018)
United States
●American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA): Guideline for the management of heart failure (2022)
●US Preventive Services Task Force (USPSTF): Final recommendation statement on statin use for the primary prevention of cardiovascular disease in adults – Preventive medication (2022)
●ACC: Expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia (2021)
●AHA/American Stroke Association (ASA): Guideline for the prevention of stroke in patients with stroke and transient ischemic attack (2021)
●American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE): Consensus statement on the management of dyslipidemia and prevention of cardiovascular disease algorithm (2020)
●AHA: Scientific statement on genetic testing for inherited cardiovascular diseases (2020)
●National Lipid Association (NLA): A scientific statement on genetic testing in dyslipidemia (2020)
●US Department of Veterans Affairs (VA) and US Department of Defense (DoD): Clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction (2020)
●ACC/AHA: Guideline on the primary prevention of cardiovascular disease (2019)
●AHA: A science advisory on omega-3 fatty acids for the management of hypertriglyceridemia (2019)
●NLA: Scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk (2019)
●AHA: Scientific statement on atherosclerotic cardiovascular disease in South Asians in the United States – Epidemiology, risk factors, and treatments (2018)
●AHA: Scientific statement on cardiovascular disease and breast cancer – Where these entities intersect (2018)
●AHA/ACC/American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)/American Academy of Physician Assistants (AAPA)/Association of Black Cardiologists (ABC)/American College of Preventive Medicine (ACPM)/American Diabetes Association (ADA)/American Geriatrics Society (AGS)/American Pharmacists Association (APhA)/American Society for Preventive Cardiology (ASPC)/NLA/Preventive Cardiovascular Nurses Association (PCNA): Guideline on the management of blood cholesterol (2018)
●AACE and ACE: Guidelines for management of dyslipidemia and prevention of cardiovascular disease (2017)
●ACC: Expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk, focused update (2017)
●AHA: Scientific statement on cardiovascular health in African Americans (2017)
●NLA: Recommendations from an expert panel on the use of PCSK9 inhibitors in adults, update (2017)
•NLA: Recommendations for patient-centered management of dyslipidemia – Part 1 (2015)
•NLA: Recommendations for patient-centered management of dyslipidemia – Part 2 (2015)
●AHA: Scientific statement on contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure (2016)
●USPSTF: Final recommendation statement on lipid disorders in children and adolescents – Screening (2016)
●AHA: Scientific statement on the agenda for familial hypercholesterolemia (2015)
●ACC/AHA: 2013 guideline on the assessment of cardiovascular risk (published 2014)
●ACC/AHA: Guideline on lifestyle management to reduce cardiovascular risk (2013)
●ACC/AHA/The Obesity Society (TOS): Guideline for the management of overweight and obesity in adults (2013)
●NLA: Clinical guidance on familial hypercholesterolemia – Screening, diagnosis and management of pediatric and adult patients (2011)
Europe
●European Atherosclerosis Society (EAS): Consensus statement on lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis (2022)
●EAS: Consensus statement on triglyceride-rich lipoproteins and their remnants – Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies (2021)
●EAS: Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients (2021)
●EAS/European Society of Vascular Medicine (ESVM): Joint statement on lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease (2021)
●European Society of Cardiology (ESC): Guidelines on cardiovascular disease prevention in clinical practice (2021)
●EAS: Consensus statement – Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights (2020)
●EAS: Consensus statement on rare dyslipidaemias, from phenotype to genotype to management (2020)
●EAS and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM): Consensus statement on quantifying atherogenic lipoproteins for lipid-lowering strategies (2020)
●European Menopause and Andropause Society (EMAS): Clinical guide for menopause symptom management in women with dyslipidemias (2020)
●ESC/EAS: Guidelines for the management of dyslipidaemias – Lipid modification to reduce cardiovascular risk (2019)
●European Society of Hypertension (ESH) and European Association for the Study of Obesity (EASO): A call for action on obesity and cardiovascular risk – Part A: Mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment (2018)
●ESC/EAS: Consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors – Practical guidance for use in patients at very high cardiovascular risk (2017)
●ESC/EAS: Practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia, update (2017)
●EAS and EFLM: Joint consensus statement – Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points (2016)
●EAS: Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease (2014)
●EAS: Position paper on homozygous familial hypercholesterolaemia – New insights and guidance for clinicians to improve detection and clinical management (2014)
●EAS: Consensus statement – Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease (2013)
●EAS: Consensus statement on the polygenic nature of hypertriglyceridaemia – Implications for definition, diagnosis, and management (2013)
United Kingdom
●National Institute for Health and Care Excellence (NICE): Guideline on cardiovascular disease – Risk assessment and reduction, including lipid modification (2023)
●NICE: Quality standard on cardiovascular risk assessment and lipid modification (2015, updated 2023)
●NICE: Clinical guideline on familial hypercholesterolaemia – Identification and management (2008, updated 2019)
●Hyperlipidaemia Education and Atherosclerosis Research Trust United Kingdom (HEART UK): Statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom (2016)
●NICE: Quality standard on familial hypercholesterolaemia (2013)
Australia–New Zealand
●Choosing Wisely Australia: Do not routinely test and treat hyperlipidemia in those with a limited life expectancy (2022)
●Cardiac Society of Australia and New Zealand (CSANZ): Position statement for the diagnosis and management of familial hypercholesterolaemia (2016)
●Choosing Wisely Australia: Don't commence therapy for hypertension or hyperlipidaemia without first assessing the absolute risk of a cardiovascular event (2015)
●Royal Australian College of General Practitioners (RACGP): Detecting familial hypercholesterolaemia in general practice (2012)
●Practical Implementation Taskforce for the Prevention of Cardiovascular Disease: Evidence-based clinical aid for the prevention of cardiovascular disease (2004)
Japan
●[In English] Japan Atherosclerosis Society (JAS): Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia (2022)
●[In Japanese] JAS: Clinical practice guidelines for adult familial hypercholesterolemia (2022)
●[In Japanese] JAS: Guidelines for prevention of atherosclerotic cardiovascular diseases (2022)
●[In Japanese] Choosing Wisely Japan: Drugs for dyslipidemia for elderly people over 75 years old – When necessary and not necessary (2016)
